The European commercialization efforts for Akcea Therapeutics Inc.’s second antisense product, Waylivra (volanesorsen), discovered by Ionis Pharmaceuticals and co-developed by the two firms, will build on the infrastructure the US-headquartered Akcea has put in place over the past year for its first antisense product, Tegsedi (inotersen, licensed from Ionis), which is just starting to garner its first sales in the region.
Tegsedi was cleared for marketing in the EU by the European Commission in July 2018 for the treatment of Stage...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?